Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Iovance Biotherapeutics is a commercial-stage cell therapy company focused on tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. The company launched AMTAGVI (lifileucel) in February 2024 for advanced melanoma, representing the first FDA-approved TIL therapy and a novel mechanism in immuno-oncology. With $0.2B in initial commercial revenue and a 13,699% YoY growth rate reflecting the transition from pre-revenue to commercial operations, the company is executing on manufacturing scale-up while burning approximately $400M annually.
Iovance generates revenue through one-time infusions of autologous TIL therapy at approximately $515,000 per treatment course. The business model requires extracting tumor tissue from patients, expanding TILs ex vivo over 22 days at centralized manufacturing facilities, then cryopreserving and shipping back to treatment centers. Pricing power derives from being first-to-market in TIL therapy with demonstrated clinical efficacy (31% objective response rate in melanoma), though reimbursement negotiations with payers and Medicare coverage determinations remain critical. The company competes against established checkpoint inhibitors and emerging CAR-T therapies, with differentiation based on mechanism of action and patient selection criteria.
AMTAGVI quarterly patient starts and revenue per treatment - commercial launch trajectory versus Street expectations
Medicare coverage decisions and commercial payer reimbursement approvals - critical for market access expansion
Manufacturing capacity utilization and cycle time improvements - ability to scale from current ~200 annual patient capacity
Phase 3 trial readouts in NSCLC (IOV-LUN-202) and endometrial cancer - pipeline validation for label expansion
Competitive data from CAR-T programs and novel checkpoint combinations in same indications
Cash runway updates and financing needs - company burning $400M annually with $1.2B+ cash position as of recent reports
Manufacturing complexity and scalability - autologous TIL therapy requires 22-day patient-specific production with specialized facilities, limiting throughput versus off-the-shelf allogeneic approaches being developed by competitors
Reimbursement uncertainty - CMS and commercial payers still establishing coverage policies for novel cell therapies, with risk of restrictive criteria or inadequate pricing that undermines unit economics
Competitive displacement risk from next-generation immunotherapies including allogeneic TILs, TCR-T therapies, and combination checkpoint regimens that may offer superior efficacy or convenience
Bristol Myers Squibb and Merck dominate melanoma treatment with established checkpoint inhibitors (Opdivo, Keytruda) that have broader label indications and simpler administration
Emerging CAR-T and TCR-engineered T-cell therapies from Adaptimmune, Kite/Gilead, and others targeting solid tumors with potentially faster manufacturing timelines
Allogeneic TIL programs from competitors could eliminate patient-specific manufacturing bottleneck, offering off-the-shelf alternatives
High cash burn rate of $400M annually with current revenue run-rate insufficient to achieve profitability - likely requires additional financing within 24-36 months
Equity dilution risk from future capital raises given $900M market cap and ongoing losses, particularly if stock remains depressed
Manufacturing capex requirements to expand beyond current ~200 patient annual capacity could accelerate cash consumption
low - Cancer treatment demand is non-discretionary and largely insulated from economic cycles. However, hospital capital budgets for new therapy adoption and payer willingness to cover premium-priced treatments can be affected during severe recessions. The company's commercial trajectory depends more on clinical evidence generation and reimbursement policy than GDP growth.
Rising interest rates negatively impact valuation multiples for pre-profitable biotech companies as future cash flows are discounted more heavily. Higher rates increase the opportunity cost of holding cash-burning growth stocks versus fixed income. Operationally, Iovance benefits from interest income on its $1.2B+ cash balance, partially offsetting burn rate, but this is minor relative to the valuation compression effect. Financing costs for future capital raises increase in higher rate environments.
Minimal direct credit exposure. The company has negligible debt (0.07 D/E ratio) and does not rely on credit markets for operations. However, tighter credit conditions can reduce biotech sector liquidity and make future equity or debt financings more dilutive. Hospital and payer financial stress could theoretically delay reimbursement, but cancer care remains prioritized.
growth - Attracts speculative biotech investors focused on commercial execution of novel cell therapy platform with significant market expansion potential if pipeline succeeds. The stock appeals to those willing to accept high volatility and binary clinical/regulatory risk in exchange for multi-bagger potential if TIL therapy gains broader adoption across solid tumors. Not suitable for value or income investors given negative profitability, no dividend, and high cash burn.
high - Biotech stocks with single commercial product and binary clinical catalysts exhibit elevated volatility. The -53% one-year return and recent stabilization reflect typical early commercial-stage dynamics. Stock moves sharply on clinical data, reimbursement decisions, and quarterly revenue beats/misses. Beta likely exceeds 1.5x relative to broader market.
